Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...
Bayer Aktiengesellschaft BAYRY announced that its investigational candidate, finerenone, met the primary endpoint in a phase III study, FIDELIO-DKD. The study evaluated the efficacy and safety of ...
George L. Bakris, MD, describes the design and results of the FIDELIO-DKD trial investigating the effect of finerenone on patients with chronic kidney disease. Neil B. Minkoff, MD: Dr Bakris, I ...
A variety of factors contributed to discontinuation rates in FIDELIO-DKD, said George Bakris, MD, professor of medicine and director of the American Heart Association Comprehensive Hypertension Center ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new cardiovascular (CV) and renal subgroup analyses for KERENDIA ® (finerenone) from the comprehensive clinical trial program, including the ...
The study evaluated finerenone in addition to standard of care in patients with chronic kidney disease and type 2 diabetes. The phase 3 FIGARO-DKD study evaluating finerenone, a nonsteroidal selective ...
Zacks Investment Research on MSN
BAYRY reports positive data on kidney drug in non-diabetic CKD
Bayer BAYRY announced that finerenone achieved the primary endpoint in the late-stage FIND-CKD study, marking a key milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results